Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

490.00 -11.72 (-2.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
53 54 Next >
Vertex Pharmaceuticals (VRTX) Q4 2022 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Why Vertex Pharmaceuticals Stock Is Moving During Tuesday's After-Hours Session
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading marginally lower by 0.82% to $306 during Tuesday's after-hours session. 
Via Benzinga
Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views
The company topped guidance expectations for its cystic fibrosis medicines. 
Via Investor's Business Daily
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The 7 Best Biotech Stocks to Buy for February 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential. 
Via InvestorPlace
3 No-Brainer Stocks to Buy in February
Going with these stocks should be an easy decision. 
Via The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today
Via Benzinga
The Best Stocks to Invest $20,000 in Right Now
These healthcare giants have plenty of room left to run. 
Via The Motley Fool
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
3 Top Stocks to Buy If There Is a Market Pullback
All three of these stocks performed well as the market fell in 2022. 
Via The Motley Fool
3 Nasdaq 100 Stocks to Buy Hand Over Fist in February
The growth-focused Nasdaq 100 is home to three exceptional deals. 
Via The Motley Fool
Is a Recession on the Way? Here's What the Top 7 Indicators Say.
If these indicators were in a Magic 8 Ball, they'd probably say, "Ask again later." 
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
3 No-Brainer Growth Stocks to Buy in 2023
These stocks all fell by double digits last year. 
Via The Motley Fool
Why Editas Medicine's Shares Jumped This Week
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
These companies should be able to carry their momentum well beyond this year. 
Via The Motley Fool
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
Is Editas Medicine Stock a Buy Now?
Layoffs and a thin clinical-stage pipeline aren't very encouraging. 
Via The Motley Fool
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade
These stocks are growing steadily and have a solid history of enriching shareholders. 
Via The Motley Fool
The 10 Best Stocks to Buy in February 2023
These diversified growth stocks could add rocket fuel to your long-term investing portfolio. 
Via The Motley Fool
A New Bull Market Could Arrive in February: 3 Stocks to Buy Now
The bulls could be about to take over again. And these stocks are poised to be big winners. 
Via The Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
The gene-therapy specialist's near-term outlook is quite bullish. 
Via The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
7 Cream-of-the-Crop Stocks to Buy Today
Fast-growing, underappreciated stocks to buy are trading at a steep discount and will reward investors as they rise in value. 
Via InvestorPlace
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength. 
Via Talk Markets
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies. 
Via The Motley Fool
BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential
BP and Chinese search leader Baidu lead this weekend's watch list. 
Via Investor's Business Daily
3 Smart Stocks to Buy if a Recession Is on the Way
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
The Best Stocks to Invest $5,000 In Right Now
It's still a great time to be a long-term investor. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.